Literature DB >> 24290569

Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes.

Milind Y Desai1, Aditya Bhonsale2, Parag Patel2, Peyman Naji2, Nicholas G Smedira2, Maran Thamilarasan2, Bruce W Lytle2, Harry M Lever2.   

Abstract

OBJECTIVES: This study sought to assess long-term outcomes in asymptomatic or minimally symptomatic patients with hypertrophic cardiomyopathy (HCM) who underwent exercise echocardiography, without invasive therapies for relief of left ventricular outflow tract (LVOT) obstruction.
BACKGROUND: Many HCM patients present with LVOT obstruction, mitral regurgitation (MR), and diastolic dysfunction, often requiring invasive therapies for symptomatic relief. However, a significant proportion of truly asymptomatic patients can be closely monitored. In HCM patients, exercise echocardiography has been shown to be a useful assessment of functional capacity and risk stratification.
METHODS: We included 426 HCM patients (44 ± 14 years; 78% men) undergoing exercise echocardiography, excluding hypertensive heart disease of elderly, ejection fraction <50% and invasive therapy (myectomy or alcohol ablation) during follow-up. Clinical, echocardiographic (LV thickness, LVOT gradient, and MR) and exercise variables (percent of age-sex predicted metabolic equivalents [METs] and heart rate recovery [HRR] at 1 min post-exercise) were recorded. A composite endpoint of death, appropriate internal defibrillator discharge, and admission for congestive heart failure was recorded.
RESULTS: Patients were asymptomatic or minimally symptomatic on history, but 82% of patients achieved <100% of age-sex predicted METs, and 43% had ≥II+ post-stress MR. The mean LV septal thickness, post-exercise LVOT gradient, and HRR were 2.0 ± 0.5 cm, 62 ± 47 mm Hg, and 31 ± 14 beats/min, respectively. During a mean follow-up of 8.7 ± 3 years, there were 52 events (12%). Patients achieving >100% of age-sex predicted METs had 1% event rate versus 12% in those achieving <85%. On stepwise multivariate survival analysis, percent of age-sex predicted METs (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.64 to 0.90), abnormal HRR (HR: 0.89; 95% CI: 0.82 to 0.97), and atrial fibrillation (HR: 2.73; 95% CI: 1.30 to 5.74) (overall, p < 0.001) independently predicted outcomes.
CONCLUSIONS: In asymptomatic or minimally symptomatic HCM patients, exercise stress testing provides excellent risk stratification, with a low event rate in patients achieving >100% of predicted METs.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AF; CHF; HCM; HR; HRR; ICD; LVOT; METs; MR; VT; atrial fibrillation; congestive heart failure; exercise echocardiography; hazard ratio; heart rate recovery; hypertrophic cardiomyopathy; implantable cardioverter-defibrillator; left ventricular outflow tract; metabolic equivalents; mitral regurgitation; outcomes; ventricular tachycardia

Mesh:

Year:  2013        PMID: 24290569     DOI: 10.1016/j.jcmg.2013.08.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  25 in total

Review 1.  Clinical topic: Nuclear imaging in hypertrophic cardiomyopathy.

Authors:  Victoria Delgado; Jeroen J Bax
Journal:  J Nucl Cardiol       Date:  2014-12-30       Impact factor: 5.952

2.  Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.

Authors:  Lars Lindholm Sorensen; Hsin-Yueh Liang; Aurelio Pinheiro; Alex Hilser; Veronica Dimaano; Niels Thue Olsen; Thomas Fritz Hansen; Peter Sogaard; Alexandra Nowbar; Chiara Pisanello; Iraklis Pozios; Susan Phillip; Xun Zhou; Roselle Abraham; Theodore P Abraham
Journal:  Am Heart J       Date:  2016-10-20       Impact factor: 4.749

Review 3.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 4.  Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Alexandros Klavdios Steriotis; Sanjay Sharma
Journal:  Eur Cardiol       Date:  2015-07

5.  Novel Imaging Techniques for Heart Failure.

Authors:  Josep L Melero-Ferrer; Raquel López-Vilella; Herminio Morillas-Climent; Jorge Sanz-Sánchez; Ignacio J Sánchez-Lázaro; Luis Almenar-Bonet; Luis Martínez-Dolz
Journal:  Card Fail Rev       Date:  2016-05

Review 6.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

7.  Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis.

Authors:  Ahmad Masri; Mohamed Kanj; Maran Thamilarasan; Oussama Wazni; Nicholas G Smedira; Harry M Lever; Milind Y Desai
Journal:  Cardiovasc Diagn Ther       Date:  2017-02

Review 8.  The role of echocardiography in hypertrophic cardiomyopathy.

Authors:  Lynne K Williams; Christiane H Gruner; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

Review 9.  Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.

Authors:  Ariane Fraiche; Andrew Wang
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

Review 10.  Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Adrián Bayonas-Ruiz; Francisca M Muñoz-Franco; Vicente Ferrer; Carlos Pérez-Caballero; María Sabater-Molina; María Teresa Tomé-Esteban; Bárbara Bonacasa
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.